The Potential Prognostic Impact and Intercorrelations between CTLA-4, PD-1/PD-L1 and CD73/A2AR Immune Checkpoint Molecules in Colorectal Cancer

被引：0
|
作者：
Aboelnasr, L. [1 ,2 ]
Abdou, A. [3 ]
机构：
[1] Menoufia Univ Hosp, Menoufia, Egypt
[2] Imperial Coll London, London, England
[3] Menoufia Univ, Menoufia, Egypt
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2023年 / 25卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
ST150
引用
收藏
页码：S140 / S141
页数：2
相关论文
共 50 条
  • [1] Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond
    Sharma, Padmanee
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Immune Checkpoints Involving the PD-1/PD-L1/L2 and CD73/A2aR Axes and the Immunosuppressive Microenvironment in DLBCL
    Wang, Xianhuo
    Zhang, Tingting
    Liu, Hengqi
    Zhang, Sicong
    Li, Lanfang
    Qiu, Lihua
    Qian, Zhengzi
    Zhou, Shiyong
    Fu, Kai
    Zhang, Huilai
    BLOOD, 2022, 140 : 6458 - 6459
  • [3] Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis
    Jin, Chunhui
    Zhu, Xiaodan
    Huang, Xiaona
    Gong, Tingjie
    Wei, Zhipeng
    You, Jianliang
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (03) : 203 - 212
  • [4] Immune Checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) Expression in Plasma Cell Myeloma
    Lee, Min Young
    Park, Chan-jeoung
    Cho, Young-Uk
    You, Eunkyoung
    Jang, Seongsoo
    Lee, Jung-Hee
    Hong, Jung Yong
    Yoon, Dok Hyun
    Suh, Cheolwon
    BLOOD, 2017, 130
  • [5] Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
    Zhang, Tingting
    Liu, Hengqi
    Jiao, Lei
    Zhang, Zhenzhen
    He, Jin
    Li, Lanfang
    Qiu, Lihua
    Qian, Zhengzi
    Zhou, Shiyong
    Gong, Wenchen
    Meng, Bin
    Ren, Xiubao
    Zhang, Huilai
    Wang, Xianhuo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [6] Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma
    Landwehr, Laura-Sophie
    Altieri, Barbara
    Sbiera, Iuliu
    Remde, Hanna
    Kircher, Stefan
    Olabe, Julie
    Sbiera, Silviu
    Kroiss, Matthias
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (09): : 2325 - 2334
  • [7] Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
    Bewersdorf, Jan Philipp
    Shallis, Rory M.
    Zeidan, Amer M.
    BLOOD REVIEWS, 2021, 45
  • [8] Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    S A Quezada
    K S Peggs
    British Journal of Cancer, 2013, 108 : 1560 - 1565
  • [9] Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    Quezada, S. A.
    Peggs, K. S.
    BRITISH JOURNAL OF CANCER, 2013, 108 (08) : 1560 - 1565
  • [10] Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors. Immune-mediated side effects
    Grimm, M. -O.
    Oppel-Heuchel, H.
    Foller, S.
    UROLOGE, 2018, 57 (05): : 543 - 551
12345